Researchers at UW-Madison are trying to repurpose an antitumor drug to treat a common intellectual disability known as Fragile X Syndrome.

And Professor Xinyu Zhao, a professor of neuroscience at UW-Madison who’s heading up this research, says initial tests in rodents show promise for this experimental treatment option.

“This could be a new way to treat, at least, cognitive function in Fragile X patients — at least worth exploring,” Zhao said.

The Wisconsin Alumni Research Foundation is seeking commercial licensing partners for the patent, which covers the use of Nutlin-3, a candidate antitumor drug, to treat Fragile X Syndrome.

See more at

Print Friendly, PDF & Email